Novo Nordisk inks research deal with RNA startup with new delivery approach

No­vo Nordisk is col­lab­o­rat­ing with RNA up­start Eleven Ther­a­peu­tics in a bid to iden­ti­fy new med­i­cines that can de­liv­er nu­cle­ic acids.

The deal, an­nounced Mon­day morn­ing, will uti­lize Eleven’s plat­form, dubbed “DE­Liv­eri,” to iden­ti­fy po­ten­tial mol­e­cules that can de­liv­er nu­cle­ic acid ther­a­peu­tics to treat undis­closed car­diometa­bol­ic dis­eases. It gives No­vo ex­clu­sive ac­cess to cer­tain cell types and ap­pli­ca­tions that are as­so­ci­at­ed with the plat­form, ac­cord­ing to a press re­lease. Fi­nan­cial de­tails were not dis­closed.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN